The Luveris In Vitro Fertilization Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to develop a new protocol using two different types of fertility drugs that is more similar to the way the hormones act in a normal menstrual cycle (period).
We are recruiting women who are trying to get pregnant through In Vitro Fertilization (IVF) who either have a high prolactin level (a hormone normally found in your blood that is produced in the brain) or have a condition known as hypothalamic amenorrhea in which one does not get regular periods due to low hormone levels.
The ovaries can be stimulated with Follicle Stimulating Hormone (FSH) alone and with FSH and Luteinizing Hormone (LH). FSH causes eggs to be made while LH causes estrogen (hormone) production. The women in this study have low hormone levels and need both FSH and LH. Luveris® (LH hormone) is a new drug approved for egg production and is used in IVF. There is no set amount of LH nor a set protocol for LH use. Therefore, we are testing this new regimen. One group of women will receive a fixed dose of LH throughout their cycle while the other will decrease the dose of FSH while at the same time increasing the LH dose which is what happens in the natural menstrual cycle.
| Condition | Intervention | Phase |
|---|---|---|
|
Infertility Hypothalamic Amenorrhea Hyperprolactinemia |
Drug: Luveris fixed dose Drug: Luveris increasing dose |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity. |
- The primary outcome will be number of large follicles (16 mm or greater in diameter) and midsize (12-15.5 mm in diameter) in both groups on the day of meeting size criteria for hCG. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Secondary outcomes include pregnancy rates, number of follicles, hormone levels on the day of hCG, days of GnRH antagonist, fertilization and implantation rates. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Group A
Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
|
Drug: Luveris fixed dose
Luveris 75IU daily throughout ovarian stimulation
|
|
Experimental: Group B
Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
|
Drug: Luveris increasing dose
Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
|
Eligibility| Ages Eligible for Study: | 18 Years to 38 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 30 women under 38 years old at time of signing Informed Consent Form.
- Evidence of hypothalamic amenorrhea (irregular menses and FSH and LH <5 mIU/mL), uncorrected hyperprolactinemia (prolactin levels 10% above the upper limit of normal) or iatrogenic hypothalamic hypogonadism secondary to GnRHa suppression.
- In good general health off of current medications which may confound response to study medications except GnRHa (Lupron Depot).
- Desire to seek pregnancy actively during the study period.
- A normal uterine cavity must have been confirmed by either hysteroscopy or hydrosonogram within two years of entering the study.
- A semen analysis on the male partner deemed adequate for IVF by the attending physician within the past year or donor sperm available for insemination.
- Only one treatment cycle per patient will be studied.
Exclusion Criteria:
- uncorrected thyroid disease.
- heart disease (New York Heart Association Class II or higher).
- a history of, or suspected cervical, endometrial, or breast cancer. A normal Pap smear result within the last 24 months will be required.
- enrolled into other studies that require medications, limit sex, or otherwise prevent compliance with the protocol at the same time.
- to take other medications known to affect reproduction.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Peter McGovern, MD, Director, University Reproductive Associates |
| ClinicalTrials.gov Identifier: | NCT00889512 History of Changes |
| Other Study ID Numbers: | 0120080358 |
| Study First Received: | April 28, 2009 |
| Last Updated: | August 19, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Amenorrhea Hyperprolactinemia Infertility Menstruation Disturbances Pathologic Processes Hyperpituitarism Pituitary Diseases |
Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases Genital Diseases, Male Genital Diseases, Female |
ClinicalTrials.gov processed this record on May 19, 2013